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The myogenic regulatory factors, Mrf4 and Myf5, play a key role in skeletal muscle formation. An enhancer trap approach, devised to
isolate positive-acting elements from a 200-kb YAC covering the mouse Mrf4–Myf5 locus in a C2 myoblast assay, yielded an enhancer, A17,
which mapped at 8 kb 5V ofMrf4 and 17 kb 5V ofMyf5. An E-box bound by complexes containing the USF transcription factor is critical
for enhancer activity. In transgenic mice, A17 gave two distinct and mutually exclusive expression profiles before birth, which correspond to
two phases of Mrf4 transcription. Linked to the Tk or Mrf4 minimal promoters, the nlacZ reporter was expressed either in embryonic
myotomes, or later in fetal muscle, with the majority of Mrf4 lines showing embryonic expression. When linked to the Myf5 minimal
promoter, only fetal muscle expression was detected. These observations identify A17 as a sequence that targets sites of myogenesis in vivo
and raise questions about the mutually exclusive modes of expression and possible promoter/enhancer interactions at the Mrf4–Myf5 locus.
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Introduction helix family of transcription factors to be expressed in theTissue specification depends on factors that determine
the entry of cells into a particular program of differentiation.
Skeletal muscle formation is initiated by the myogenic
regulatory factors, which control both determination and
differentiation of this tissue (reviewed in Buckingham,
2001). Myf5 is the first member of this basic helix–loop–0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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73, D14195 Berlin, Germany.mouse embryo, where it plays a key role as a determination
factor at the onset of myogenesis (Braun et al., 1992;
Tajbakhsh et al., 1996a,b). Later, MyoD also plays this role;
when both Myf5 and MyoD genes are mutated, the precursor
myoblast population is absent and skeletal muscles do not
form (Rudnicki et al., 1993). Another myogenic factor gene,
Mrf4, is linked to Myf5 in the same locus (Braun et al.,
1990; Miner and Wold, 1990). Mrf4 is thought to regulate
muscle cell differentiation (Black et al., 1995; Naidu et al.,
1995). This is clearly the function of Myogenin, the fourth
member of the family (Hasty et al., 1993; Nabeshima et al.,
1993). However, the differentiation of the early myotomal
muscle appears to depend on Mrf4 rather than Myogenin
(see Buckingham, 1994; Patapoutian et al., 1995) and in the
MyoD//Mrf4/ double mutants, most skeletal muscle
fibers fail to form (Rawls et al., 1998), indicating that
Myogenin cannot compensate for the absence of both these
factors. Recently, the analysis of an allelic series of mutants
in the Mrf4–Myf5 locus suggests that Mrf4 also acts as a
determination factor at the onset of myogenesis in the
embryo (Kassar-Duchossoy, Buckingham and Tajbakhsh,
in preparation).
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muscle formation and maturation (Tajbakhsh and Bucking-
ham, 2000). Muscle progenitor cells derive from somites,
which are formed by progressive segmentation of paraxial
mesoderm, following a rostrocaudal gradient on either side of
the axial neural tube and notocord, such that the oldest and
most mature somites are situated cranially. Newly formed
epithelial somites develop an epithelial dermomyotome,
adjacent to the surface ectoderm, which gives rise to dermis
and muscle, and a ventral sclerotome composed of mesen-
chymal cells that will contribute to cartilage. Muscle progen-
itor cells present in the epaxial dermomyotome, adjacent to
the axial structures, are the first to delaminate, to form the
myotome, a skeletal muscle that underlies the dermomyo-
tome and will later contribute to the deep back muscles.Myf5
is expressed in these cells in the epaxial dermomyotome.
Shortly afterwards, bothMyf5 andMrf4 are activated in cells
in the opposite, hypaxial, edge of the dermomyotome. These
cells will also contribute to the myotome and to the formation
of most trunk muscles. As the somite matures, the dermo-
myotome elongates, such that the first epaxial cells to
delaminate are now in the central region of the myotome.
This is where differentiation is initiated, with expression of
Mrf4. This central or intercalated domain of the dorsal somite
is characterized by the expression ofEngrailed1, and presents
interesting analogies with the adaxial territory of the zebrafish
somite (Spo¨rle, 2001). At the limb level, muscle progenitor
cells migrate from the somite into the limb field where they
subsequently activate Myf5. Muscle progenitor cells delam-
inate and move away from anterior somites to form the
hypoglossal cord on either side of the axis. These cells, which
already express Myf5, contribute to tongue and pharynx
muscles. Head muscles, such as those of the jaw, form from
unsegmented paraxial mesoderm, from Myf5-positive cells
initially present in the branchial arches. As skeletal muscles
form and mature during fetal stages, Myf5 continues to be
transcribed at a lower level (Tajbakhsh et al., 1996c)Mrf4, on
the other hand, is expressed at very low levels in embryonic
muscles, with the exception of the myotome; its transcripts
accumulate during a second major wave of expression in
muscle fibers from fetal stages (Bober et al., 1991; Hinter-
berger et al., 1991).
The control of the Mrf4–Myf5 locus is complex, with
some regulatory sequences in the intra- and intergenic regions
and others at a considerable distance 5V to the genes. The
early expression of Myf5 in the dermomyotome depends on
an epaxial enhancer situated just 3V of Mrf4 and 6 kb 5V of
Myf5 (Summerbell et al., 2000; Teboul et al., 2002). An
element that directs transcription of Myf5 in the branchial
arches is also present in the intergenic region (Summerbell et
al., 2000). Situated at 58/48 kb from Myf5 is a sequence
containing elements that direct expression of the gene in the
limbs, intercalated myotome and epaxial and hypaxial ex-
tremities of the mature dermomytome (Buchberger et al.,
2003; Hadchouel et al., 2000, 2003). Further sequences that
direct transcription of Myf5 in the earlier hypaxial dermo-myotome are present both within the gene (Summerbell et al.,
2000) and at a distance from it (>88 kb) (Carvajal et al.,
2001). Also, in this far upstream region (96/63 kb) are
elements that are necessary for the maintenance of Myf5
expression in head and most trunk muscles in the fetus
(Carvajal et al., 2001; Hadchouel et al., 2000). Elements that
regulateMrf4 transcription have been described in the region
immediately 5V to the gene. A 6.5-kb sequence 5V to the
mouse Mrf4 gene is sufficient to direct the second wave of
fetal expression (Patapoutian et al., 1993) and discrete muscle
enhancers active in myoblast cultures (Kerkvliet and Hinter-
berger, 1997) and in embryos have been identified in this
region (Pin and Konieczny, 2002). An 8.5-kb sequence 5V to
the ratMrf4 gene similarly directs reporter gene expression in
fetal muscles of transgenic mice and also in cells of the
myotome (Pin et al., 1997), suggesting that the first wave of
Mrf4 transcription depends on element(s) situated between
8.5 and 6.5 kb from the gene. In addition, further
upstream elements within 132 kb from the Mrf4 gene have
been implicated, by deletion analysis, in aspects of its
expression in the somite (Carvajal et al., 2001).
Multiple regulatory sequences are therefore present
throughout the Mrf4–Myf5 locus and this has complicated
the interpretation of targeted mutations in either gene (see
Olson et al., 1996; Yoon et al., 1997). In addition, 3V exons
of a large protein tyrosine phosphatase gene, Ptprq (Wright
et al., 1998), lie upstream (23 kb) ofMrf4. This gene is not
expressed in skeletal muscle, indicating that it is regulated
independently. It is not yet clear to what extent sequences
identified in the context of either Myf5 or Mrf4 regulation
may affect the promoter of the other myogenic factor gene.
Deletions of large YACs or BACs with nlacZ targeted to
Myf5, which recapitulate expression of the endogenous
gene, demonstrate that the intergenic epaxial enhancer and
the 58/48 kb region are essential for important aspects of
Myf5 transcription in the embryo (Hadchouel et al., 2003;
Teboul et al., 2002).Mrf4 does not appear to be expressed in
the epaxial dermomyotome, and therefore is probably not
regulated by the early epaxial enhancer, and although the
58/48 kb sequence may interact with the Mrf4 promoter,
it does not do so to the same extent, given the differences in
expression levels of the two genes in early limb muscles, for
example (see Tajbakhsh and Buckingham, 2000). The
different expression profiles of Mrf4 and Myf5 would point
to mechanisms of enhancer–promoter selection.
We describe here an alternative strategy to the long range
YAC/BAC deletion approach for identifying regulatory
sequences around the Mrf4–Myf5 locus. Based on an en-
hancer trap assay in cultured muscle cells, we have isolated a
sequence (A17) situated at 17 kb from Myf5, which acts as
an enhancer, with a 15-bp core sequence containing a critical
E-box that binds USF complexes. In vivo, this enhancer is
active, directing an nlacZ transgene with a nonmyogenic Tk
promoter either to the early intercalated myotome or later to
fetal muscle fibers. The mutual exclusion of these two modes
of expression is also seen with theMrf4 andMyf5 promoters;
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whereas with the latter the enhancer only directs expression in
muscle from fetal stages in the transgenic lines analyzed.
These results have implications both for the regulation of
myogenesis at the sites targeted by the enhancer and for
promoter/enhancer interactions in the Mrf4–Myf5 locus.Materials and methods
Cell culture and transfections
C2/7 myoblasts (Yaffe and Saxel, 1977) and 10T1/2 cells
were grown in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco) containing 20% fetal calf serum (FCS)
(Gibco). U2OS osteosarcoma cells were grown in DMEM
containing 10% FCS. C2 myoblasts in confluent cultures
were induced to differentiate into myotubes by changing to
DMEM/2% FCS. Cells seeded onto 60-mm dishes (Falcon)
were transfected by the calcium phosphate method as de-
scribed in Chang et al. (1997). Transfection of myotube
cultures was performed 5 days after switching to differenti-
ation medium. Typically, 10 Ag of reporter plasmid was
cotransfected with 1 Ag of pRSV-luciferase (Biben et al.,
1994) per dish as a control for transfection efficiency, and cell
extract harvested for quantification as described in Kelly et al.
(1997). h-Galactosidase and human placental alkaline phos-
phatase activity of extracts were quantified using the Galacto-
Light and PhosphaLight chemiluminescent reporter kits
(Tropix, Bedford, MA), respectively, according to manufac-
turer’s instructions. Luciferase activity was performed as
described in Biben et al. (1994), and all luminescent samples
were measured in a Lumat LB9501 luminometer. C2 cell
injections were performed as described in Lazaro et al.
(1997), and stable G418-resistant clones selected for 10 days
in 700 Ag/ml G418 (Gibco).
Fluorescent in situ hybridization (FISH) analysis
Cells of C2-YAC clones were arrested at metaphase by
addition of colcemide for 2 h (Serva). Chromosome spreads
were prepared by repeated fixation of cells with 1:3 acetic
acid/methanol and spreading cells on precleaned glass slides
(see Kappler et al., 1998 for details). FISH was performed as
in Scherthan et al. (1994), but total YAC DNAwas prepared
and biotin-labeled using a BioNick nick translation kit (Life
Tech). Labeled DNA (300 ng) was suspended in 10 Al of
hybridization solution (50% formamide, 2 SSC, 10%
dextran sulfate, 4 mg/ml mouse Cot1 DNA). Slides and
probes were denatured separately at 70jC for 3 min and
hybridization solution was applied to the slide. After 48-
h hybridization, preparations were washed and hybrid mol-
ecules detected with avidin-FITC (Sigma). Two-color FISH
with biotinylated mouse chromosome 10 paint probe (Oncor
P6110-B.5) and digoxigenin-labeled YAC probe was per-
formed in similar fashion (Kappler et al., 1998). Chromo-somes were embedded in Antifade solution (Vector)
containing 0.5 Ag/ml DAPI as DNA-specific counterstain
and analyzed using a Zeiss Axioskop fluorescence micro-
scope. Pictures were recorded with ISIS software (MetaSys-
tems) controlling a CCD camera (Hamamatsu).
Plasmid construction and mutagenesis
The Myf5-nlacZ reporter plasmid was constructed by
subcloning a 3.5-kb XbaI promoter-nlacZ fragment of the
Myf5 targeting construct as in Tajbakhsh et al. (1996b) in the
XbaI site of pBluescript II SK() or pSK (Stratagene),
followed by an SV40 polyA signal inserted in the SpeI site.
TheMrf4-AP reporter plasmid was constructed by inserting a
PCR-amplified, 385-bp mouse Mrf4 promoter in front of the
human placental Alkaline Phosphatase-SV40 polyA cassette
used in Sharpe et al. (1998), into pSK from the XbaI site to the
EcoRI site. The Tk-nlacZ reporter plasmid is as described in
Hadchouel et al. (2003). For all reporter constructs, enhancer
elements were inserted at NotI sites upstream of the reporter.
The A17 enhancer was PCR amplified from its pTk-GFPneo
trap vector (Primig et al., 1998) using primers containing a
5Vflanking NotI site (5V-CCGCTCGAGGCGGCCGCG-
GGATCCCTGGTCATATGAAACAC-3V) and a 3V flanking
EagI site (5V-CCGGATCCACGGCCGAGATCACATG-
GCACATATTTGGTT-3V). The Myf5 proximal branchial
arch enhancer (NheI–BsaBI fragment as described in Sum-
merbell et al., 2000) was PCR amplified, similarly adding
flanking 5VNotI and 3VEagI sites. Amplified fragments were
digested with EagI for ligation into vector NotI sites, con-
serving only a 5V NotI site for successive insertions, and
products of PCR amplification were verified by sequencing
(Genome Express, Montreuil, France). An identical PCR
strategy was used to generate A17 deletion mutants at the
chosen nucleotides. In the case of A17D, nucleotides 1 to 508
were PCR amplified with a flanking 5V NotI site and a fused
3V XbaI site and inserted into pSK. Subsequently, nucleotides
526–583 were amplified with a flanking 3V EcoRI site and
fused 5V XbaI site and inserted into the intermediate construct
to generate a core-deleted A17Dmutant such that nucleotides
509–525 are replaced by an adenosine residue.
Site-directed mutagenesis on A17 was performed from a
pSK-A17 plasmid using a PCR-based QuikChange muta-
genesis kit (Stratagene) and oligos with complementary
mutations in this sequence: 5V-GTCGGTAAGTTTCTTA-
TAGTTGATTGACTCACATGACGTGCTTTGTTTAAC-
3V. A17mutants were screened by restriction assays, verified
by sequencing, and subcloned into reporter constructs.
Gel mobility shift assay (GMSA)
The 31-bp, double-stranded GMSA probe spanning the
wild-type A17 core was generated by annealing a 29-bp sense
oligo (5V-AGTTTCTTATGATTGACTCACATGACGTG-
3V) with a 29-bp antisense oligo (5V-AGCACGTCATGT-
GAGTCAATCATAAGAAA-3V) such that the 5V single-
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incubation with Klenow polymerase (New England Biolabs)
and radiolabeled [a32P]-dCTP and [a32P]-dTTP (Amersham)
for 1 h at 37jC. Probes and nonradioactive cold competitor
dsDNAs were purified in Chromaspin-10 gel filtration spin
columns (Clontech). Mutated probes and cold competitors, as
indicated in the results section, were generated in identical
fashion. C2 nuclear extract was prepared as described in
Schreiber et al. (1989), and procedures for binding extract to
probe, and polyacrylamide gel electrophoresis were as de-
scribed in Catala et al. (1995). Three micrograms of protein
extract (quantified by Bradford assay) and 2 ng of labeled
probe per reaction were used. In supershift assays, 1 Al of
antibody solution was added and incubated with the reaction
for 10min on ice before addition of labeled probe. Antibodies
used were purified rabbit antisera against Myf5 (48234; C-
terminal, as used in Kitzmann et al., 1998) and Mrf4 (48185;
C-terminal), antisera against domains F, G,M, and Z of USF1
or USF2 as described in Viollet et al. (1996), and monoclonal
antibodies against Myogenin (Wright et al., 1991), against
Pbx1/Pbx2/Pbx3 (sc888X supershift reagent, Santa Cruz
Biochemical), and against murine MyoD1 (M3512, Dako).
Mouse transgenesis, embryo staining, in situ hybridization
Transgenic mice were generated by microinjection of
purified DNA fragments into fertilized (C57BL/6J X SJL)
F2 eggs using standard techniques, as described in Hadchouel
et al. (2000). Injected eggs were reimplanted the day after
injection into pseudopregnant (C57BL/6J X CBA) F1 foster
mothers. Transgenes were identified by PCR from mouse
tails using a primer situated in lacZ as described in Tajbakhsh
et al. (1997), paired with a primer situated in the promoter of
either Myf5 (Tajbakhsh et al., 1997), Mrf4 (5V-CCCCGCA-
CAGGTAGGCCGTGGCTGTGGC-3V) , or Tk (5V-
GGCCTCGAACACCGAGCGACCCTGCAGC -
GACCCGC-3V). Transgene expression was analyzed as
described in Hadchouel et al. (2000), and in situ hybridization
on transgenic embryos was carried out as in Tajbakhsh et al.
(1997), except that the embryos were X-gal stained (Taj-
bakhsh et al., 1997) before overnight fixation in 4% PAF and
subsequent hybridization. Controls to show the full extent of
Myf5 expression were either the Y200-Myf5-nlacZ YAC line
(Hadchouel et al., 2000) or Myf5-nlacZ heterozygotes in
which one allele of Myf5 had been targeted with nlacZ
(Tajbakhsh et al., 1996a,b). The En1 in situ probe was as
described in Acampora et al. (1998). All images were
generated either by scanning (Polaroid SprintScan35) Kodak
Ektachrome 64T slides or captured by a Zeiss Axiocam CCD
camera using Zeiss Axiovision 3.0.6 SP3 software.Results
An enhancer trap assay was devised to screen for small,
positive DNA regulatory elements in the Mrf4–Myf5 locus,which are active in muscle cells (Primig et al., 1998). A
Yeast Artificial Chromosome (YAC) containing 190 kb of
mouse genomic sequence upstream and 10 kb downstream
of Myf5 had been targeted at the ATG of Myf5 with the
nlacZ reporter gene that expresses nuclear localized h-
galactosidase. In transgenic mouse embryos, the expression
profile of YAC y200-Myf5-nlacZ recapitulates that of Myf5,
demonstrating that the elements required for Myf5 regula-
tion in vivo are contained in the YAC (Hadchouel et al.,
2000). A Bacterial Artificial Chromosome (BAC) with a
similar mouse genomic sequence was shown to be sufficient
for directing correct expression of the closely linked Mrf4
gene as well (Carvajal et al., 2001).
Since the screen for regulatory elements contained within
the YAC was to be performed in the mouse C2 muscle cell
line, we first tested for reporter expression in C2 myoblasts,
which expressMyf5. The YAC used contains a neo selectable
marker gene, permitting the selection of C2 cells that have
incorporated it into their genome. When stained with X-gal,
G418-resistant colonies were h-galactosidase-positive (blue)
(Figs. 1A–B), thus confirming that sequences necessary for
Myf5 transcription in C2 cells are present in the YAC.
Previous transfections using 5.5 kb of Myf5 upstream se-
quence showed that this is essentially inactive in these cells
(S.T. unpublished). To ensure that the YAC had not recom-
bined homologously into the endogenous Mrf4–Myf5 locus,
FISH (fluorescent in situ hybridization) analysis was per-
formed on the chromosomes of normal C2 myoblasts and of
seven different clones, using a YAC-containing yeast DNA as
a Myf5 probe and a mouse chromosome (MMU) 10 paint
probe, which marks the chromosome containing the endog-
enous Myf5 gene. Twenty well-hybridized metaphase prepa-
rations were scored for signals. In all clones tested, the Myf5
probe (red) colocalized with the paint signals (green) of the
four endogenous chromosomes 10 of the tetraploid C2 cell
line (Fig. 1C), and in addition, we noted a Myf5-specific
signal on a different chromosome denoting the ectopic
integration site of the YAC (Fig. 1D). This demonstrates that
the YAC integrated in a nonhomologous chromosome in the
genome of the C2 cell clones where it directs nlacZ expres-
sion from its own myogenic regulatory elements. The FISH
experiments with the YAC clone revealed only one FISH
signal at MMU 10D1, the endogenousMyf5 locus, indicating
that the Myf5 YAC used in the experiments was specific for
this locus.
Fragments of purified y200-Myf5-nlacZ YAC DNA were
generated by a Sau3A partial digestion, and size-selected
through Sepharose spin columns to yield fragments of 2 kb
or smaller. A library was created by inserting these frag-
ments into the BamH1 site of a pTk-GFPneo trap vector in
front of the minimal promoter of the Thymidine kinase (Tk)
gene from Herpes Simplex virus (see Luckow and Schutz,
1987). The insertion of an enhancer directs expression of a
GFP-neo fusion protein that permits an antibiotic- or fluo-
rescent-based selection of positive clones. In the C2 cell
system, stable transfection of similar constructs containing
Fig. 1. C2 muscle cells express the YAC from a nonhomologous integration site distinct from the Mrf4–Myf5 locus. (A, B) C2 cells injected with y240-Myf5-
lacZ, in which Myf5 is targeted with a lacZ reporter gene, show h-galactosidase activity in G418 selected colonies, such as YC108 (A) and YC20 (B). Scale
bars represent 10 Am. The y240-Myf5-lacZ YAC used in these early experiments gives the same expression profile in vivo as YAC y200-Myf5-nlacZ
(Hadchouel et al., 2000). (C, D) Painting of mouse chromosomes 10 by FISH (FITC, green) and FISH with the Myf5 YAC (rhodamine, red) identifies the
endogenousMyf5 locus at MMU 10D1 (arrows) in a tetraploid C2 cell (C, control). In a C2 cell, which has been injected with y240-Myf5-lacZ, such as in clone
YC103, the YAC integration occurred on another mouse chromosome where it creates a strong red FISH signal (yellow arrowhead) (D, 103). The round
structure in the center of the lower image corresponds to an interphase nucleus.
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(Goldhamer et al., 1995) produced an increased number of
colonies and an increased average size of stably selected
clones, easily discernable visually (Primig et al., 1998).
The YAC-trap library was transformed into bacteria and
individual colonies gridded out at 200–250 colonies per
transformation. Assuming an average fragment size of 1 kb,
seven such transformations would yield a total pool of about
1500 colonies with a total DNA content of 1500 kb, essen-
tially covering the y200-Myf5-nlacZ sequence 7-fold. DNA
was purified from each pool of approximately 200 colonies
and transfected into C2 cells, which were selected for 7 days
in G418, fixed and stained on the dish with crystal violet to
visualize colony size and number. Two such pools, A and G,
demonstrated slightly above average colony-forming effi-
ciency, compared to a control transfected with pTk-GFPneo.
From replica plates of dishes containing pool A and pool G,
plasmid DNA was harvested from quadrants representing
approximately 50 clones, and each of these subpools was
again stably transfected into C2 cells. By reiterating this
process of positive subpool selection, single colonies that
gave a positive signal in C2 cells were finally obtained.
Their DNAwas sequenced and mapped onto y200-Myf5-
nlacZ by Southern blot analysis. The most active of the
enhancer clones (A17) was captured twice independently,
and mapped to 17 kb from the Myf5 ATG. The remaining
clones were discarded either because they were part of amouse genomic LINE1 repeat element (situated 75 to 66
kb 5V of Myf5) or else mapped too far from the Myf5 gene,
and by inference Mrf4 as well, to be implicated in their
regulation, based on knowledge obtained from successive
YAC deletions (Hadchouel et al., 2000).
Enhancer characterization in vitro
Themouse DNA sequence inA17 corresponds to a 583-bp
Sau3A fragment that contains several potential transcription
factor binding sites (Fig. 2A). To assay enhancer activity, the
fragment was subcloned into nlacZ reporter vectors driven by
either the 170-bp Tk minimal promoter used previously, the
291-bpMyf5minimal promoter (Summerbell et al., 2000), or
the 385-bp Mrf4 minimal promoter (Black et al., 1995).
Reporter gene expression, measured as h-galactosidase ac-
tivity and corrected for transfection efficiency using an RSV-
luciferase control vector, was typically increased 10- to 30-
fold, compared to the promoter alone, in the presence of the
A17 sequence with all three minimal promoters in C2 muscle
cells. This was comparable to the increase seen with the
MyoD core enhancer (Goldhamer et al., 1995) or the RSV
enhancer (Gorman et al., 1982) in parallel experiments. The
A17 sequence also functioned, with about one-third efficien-
cy, when inserted into an nlacZ expression vector in the
opposite orientation. Enhancer activity was not confined to
muscle cells, but was also seen with 10T1/2 mouse embry-
Fig. 2. Characterization of the A17 sequence. (A) The DNA sequence of the A17 enhancer. The sequence is shown in the genomic 5V to 3V orientation. E-boxes
are boxed. The potential Pbx homeodomain binding site is underlined. A Gli-like binding site is boxed with a dotted line. AP-1 binding sites are encircled. The
enhancer core at nt 511–526 is shown in boldface. (B) The 120-bp 3V fragment of A17 is necessary and sufficient for enhancer activity. 5V and 3V deletions of
A17 were cloned into a Tk-promoter nlacZ reporter construct and assessed for enhancer activity by transfection into C2 myoblasts. Enhancer activity relative to
the 583-bp control (100%) is shown for a typical trial. Transfection efficiency has been normalized relative to an RSV-luciferase control. The results shown are
the average of duplicate measurements in a typical experiment. Similar results were obtained in five other series of transfections. (C) The E-box in the 120-bp
fragment is critical for A17 enhancer activity. Point mutations within the 120-bp fragment, with the substituted bases shown in lower case, were created in the
context of the whole 583-bp enhancer, and cloned into aMyf5 minimal promoter (291-bp)-nlacZ reporter construct for assessment of enhancer activity. Relative
activities of constructs carrying mutations destroying the homeodomain binding site (HD), AP-1 site (AP), E-box (E), or combinations thereof, are indicated for
a typical trial. Activity of the unmutated sequence is taken as 100%. Transfection efficiency has been normalized relative to an RSV-luciferase control. The
results shown are the average of duplicate measurements. Similar results were obtained in nine other experiments.
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osteosarcoma cells (about 50-fold activation). In cultures of
differentiated C2 myotubes, in contrast to C2 myoblasts, the
A17 sequence only gave a twofold enhancement at most with
the Myf5 minimal promoter. When linked to a reporter
construct expressing the human placental Alkaline Phospha-
tase reporter gene from the Mrf4 minimal promoter, a
consistent 5-fold enhancement was seen in the presence of
A17. A series of deletions of A17 from both the 5V and 3V end
were assembled using PCR-amplified subfragments and
cloned into a Myf5 minimal promoter-nlacZ reporter vector.
The activity of these fragments relative to the whole A17
sequence shows that 120 bp at the 3V end are both necessary
and sufficient for enhancement of reporter gene expression inC2 myoblasts (Fig. 2B). More 5V sequences may contain
elements which repress A17 activity.
Within this 120-bp sequence, there are several transcrip-
tion factor binding motifs (Fig. 2A). Notably, a 15-bp
sequence contains a candidate homeodomain binding site
overlapped by an AP-1 site, which in turn overlaps with an
E-box motif. A mutation (A17D) in which this 15-bp core
(nucleotides 511–525) is replaced by a single adenosine
residue (to reconstitute an XbaI site for diagnostic purposes)
in the context of the complete 583-bp enhancer was con-
structed and measured for enhancer activity. A17D showed
no significant enhancer activity relative to an nlacZ reporter
construct with the promoter alone, thus identifying the 15-
bp core as critical for activation (Fig. 2C).
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were designed to disrupt the homeodomain site only (M1),
the homeodomain site and AP-1 site (M2), the AP-1 site
only (M6), the AP-1 site and E-box (M3), the E-box only
(M4), or all of these sites (M5). The activity of these
constructs in C2 myoblasts is shown in Fig. 2C. The
mutation affecting all these sites (M5) abolished enhancer
activity. Mutations affecting the homeodomain (e.g., M1,
M2) tended to increase activity. Mutation of the AP-1 site
(e.g., M2, M6), which should abolish all activity (Schu¨le et
al., 1990), had little or no effect, whereas a mutation that
affected the AP-1 site and the E-box (M3) reduced reporter
gene expression to the level seen when the 15-bp core
sequence was deleted (A17D). Mutation of the E-box alone
(M4) reduced but did not abolish enhancer activity.
To examine protein binding to these sites in the 15-bp core
sequence, electrophoretic gel mobility shift assays (GMSA)
were performed on a 3V end-labeled, 31-bp double-stranded
oligonucleotide spanning the core sequence, using nuclear
extract prepared from C2 myoblasts (Fig. 3A). Two shifted
complexes, A and a doublet B,were competed by the identical
unlabeled oligonucleotide. Neither complex could be com-
peted by the mutant sequence M5, at up to 100-fold excess.
Mutant M3, which affects the E-box and AP-1 site, showsFig. 3. A USF complex binds to the E-box in the 15-bp core of the A17 enhancer. (A
A17 enhancer binds complex A and a doublet, complex B, in gel mobility shift ass
concentrations (10, 50, 100) of the cold probe itself (wt) and of DAP, which
which all the candidate-binding sites are mutated (Fig. 2C), does not compete. M3 (
but only slightly affects complex A. DE, is an oligonucleotide of the wild-type seque
Mutant radioactive probes corresponding to M3 and DE do not bind complex A co
both A and B whereas M5 binds neither. With DE and DAP, an additional complex m
type probe. Complex A can be supershifted by antisera against USF1 (M) or USF2 (
and myogenic regulatory factors Myogenin (Mg),MyoD (Md),Mrf4 (M4) andMyf5
C2 myoblasts transfected with 10 Ag of an A17-Tk-nlacZ construct (taken as 100%)
negative (dn) USF1 (TDU1) or USF2 (TDU2) expression plasmids, deficient in tra
activity. Results with 5 Ag are the average of two experiments each with duplicatevery little competition of complex A. A competitor oligonu-
cleotide in which the internal nucleotides of the E-box are
deleted (DE) is still capable of competing complex B but does
not affect complex A. Another competitor oligonucleotide,
deleted for the core of the AP-1 site (DAP) but not affecting
the E-box, competes complex A and almost all of B, strongly
suggesting that the AP-1 site is dispensable for protein
binding. GMSA assays, using the same mutant sequences
as labeled probes, confirmed that the E-Box is required
for binding of complex A and that the AP-1 site is dispensable
for binding of all observed complexes (Fig. 3A). Since
oligonucleotide M5, which is mutated for all three binding
sites, does not bind either complex as a probe and cannot
compete either complex as a competitor, it is inferred that
complexBmust bind the homeodomain site of the 15-bp core,
as indicated by binding to the M3 mutant sequence (Fig. 3A).
Gel supershift assays were performed with antibodies
against candidate binding proteins to elucidate the composi-
tion of the complexes and particularly complex A (Fig. 3B).
Antibodies against the myogenic regulatory factors Myf5,
Mrf4, Myogenin and MyoD, which bind to E-boxes
(reviewed in Weintraub et al., 1991) failed to shift either
complex A or B. They also did not transactivate the A17
enhancer (results not shown). Since both experiments were) A radioactive (**) wild-type probe spanning the 15-bp core (boxed) of the
ays (GMSA) with C2 myoblast extracts. These are competed by increasing
contains a deletion (ACT) that eliminates the AP-1 site. In contrast, M5, in
Fig. 2C), in which the AP-1 and E-boxes are mutated, eliminates complex B,
nce with a deletion (CAT) in the E-box, which does not compete complex A.
mpared to the unmutated A17 enhancer (wt). A radioactive DAP probe binds
igrates more slowly than A. (B) GMSA are shown with the radioactive wild-
F, G, Z), but not preimmune serum (PI). Antibodies against Pbx1/Pbx2 (Pbx),
(M5) do not supershift the core binding complexes. (C) Enhancer activity in
is downregulated in a dose-dependent manner by cotransfection of dominant-
nsactivation. Transfection efficiency is normalized relative to RSV-luciferase
measurements. SEM indicated with error bars.
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from the Creatine Phosphokinase enhancer responds posi-
tively, these results suggest that the E-box in the core
sequence is not regulated by the myogenic factors. Pbx
homeodomain complexes have a consensus binding site
similar to that of the homeodomain site in the enhancer core
(Knoepfler and Kamps, 1997) but antibodies to Pbx also did
not give a shift with either complex A or B. In contrast,
antisera specific to either USF-1 or USF-2 were both capable
of shifting nearly all of complex A in the supershift assay.
USF transcription factors (Sawadogo and Roeder, 1985)
bind E-boxes as homodimers, heterodimers of USF1 and
USF2, or as heterodimers with other bHLH-Leucine zipper
transcription factors. Because USF dimers bind DNA and
transactivate promoters through different and separable
domains, dominant-negative (dn) USF expression vectors
have been constructed, which are either deficient in trans-
activation (TDU1 and TDU2) or deficient in transactivation
and DNA-binding (DbTDU1 and DbTDU2) (Lefrancois-
Martinez et al., 1995). Ectopic overexpression of these
mutants, which retain the ability to dimerize through their
HLH-Leucine Zipper domain, titrates endogenous activity of
USF and USF-partner proteins. Cotransfection of transacti-
vation deficient mutants of either USF1 (TDU1) or USF2
(TDU2) along with an A17-Tk-nlacZ reporter construct in C2
myoblasts was sufficient to extinguish enhancer activity in a
dose-dependent manner (Fig. 3C). A similar result was
obtained with the DNA-binding defective mutant (not
shown). This implies that the USF family of transcription
factors bind the E-box in the core sequence of the enhancer
and may be responsible for its transactivation in C2 cells.
Cotransfection of wild-type USF1 and USF2 expression
vectors did not increase transactivation (data not shown),
which we attribute to large endogenous pools of USF proteins
present in C2 cells.
A17 enhancer activity in vivo
To obtain a first indication of A17 enhancer activity in
vivo, transient transgenic embryos with the A17-Tk-nlacZ
fragment were assayed for activity at embryonic day (E)11.0.
h-Galactosidase activity was seen in a subregion of the
epaxial myotome following the rostral-caudal gradient of
somite maturation (Fig. 4A). We therefore developed lines
with the 583-bp A17 enhancer directing nlacZ expression in
conjunction with the Tk, Myf5, or Mrf4 minimal promoters
used previously. About 70% of PCR-positive transgenic
lines did not express the transgene, suggesting that the
enhancer sequence may be subject to integration site silenc-
ing. Four A17-Mrf4-nlacZ lines, three A17-ba-Myf5-nlacZ
lines, and one A17-Tk-nlacZ line were produced, which
showed enhancer activity.
Transgene expression was also tested after deletion of the
15-bp core sequence from the A17 enhancer (A17D). In this
case, the element (ba) at 1.8/0.7 kb from the Myf5 ATG,
which drives reporter gene expression specifically in thebranchial arches (Summerbell et al., 2000), was placed in
front of the Tk minimal promoter to provide an internal
positive control. In five transient transgenic embryos, in
which the transgene was expressed correctly in the branchial
arches, no additional myogenic expression was seen at E10.5
(Fig. 4B).
Of the four Mrf4 promoter (385 bp) lines, three express
the nlacZ reporter in embryonic myotomes. Two lines, 43M
and 44F, are phenocopies and presented in Fig. 4C. X-gal
staining is first detectable in the epaxial myotome at E8.75
(15 somites), when a few h-galactosidase positive cells are
seen in the more mature rostral somites, from about somite
XII, where somite I is the most recently formed (results not
shown). At E10.75 and E11.5, the transgene continues to be
expressed in myotomes from somite X as seen at E9.75. At
E11.5, weak hypaxial expression was also detected in addi-
tion to strong epaxial labeling. h-Galactosidase activity is
gradually lost in the most mature somites as development
proceeds. At E12.5, there is residual X-gal staining more
rostrally, but only the more caudal somites from the hind
limb level are still strongly expressing the transgene. By
E14.5, no h-galactosidase-positive cells are detectable ex-
cept in tail somites (results not shown). As seen in Fig. 4C,
only a subdomain of the myotome is labeled at E11.5,
compared with an embryo where transgene expression is
directed by all the regulatory sequences present in YAC
y200-Myf5-nlacZ (Fig. 4D). This central epaxial territory
resembles that of the intercalated domain, characterized by
the extent of Engrailed1 expression in the dorsal somite
(Spo¨rle, 2001). To examine this more closely, E10.75 em-
bryos of line 43M were stained with X-gal and subsequently
hybridized in situ with an Engrailed1 riboprobe (purple).
Cells expressing the transgene, which are h-galactosidase-
positive, lie within the Engrailed1 expression domain (Fig.
4F), and thus constitute a subdomain of Myf5 expression in
the myotome (Fig. 4E). The third A17-Mrf4-nlacZ line, 1F,
with X-gal staining in the myotome, shows much higher
levels of transgene expression. The full extent of the myo-
tome is labeled and there is also ectopic expression in the
neural tube and dorsal root ganglia (results not shown).
Myotome labeling outside the intercalated domain may
correspond to lower levels of h-galactosidase activity, which
are not easily detectable in the other two transgenic lines,
perhaps reflecting persistence of the protein in cells that no
longer transcribe the transgene. In line 1F, also, labeling in all
but the least mature somites is no longer detectable by fetal
stages of development (E13) (results not shown). The ex-
pression profile, characterized by myotomal labeling in the
embryo (Fig. 4), reflects the first wave of Mrf4 expression
(Bober et al., 1991; Hinterberger et al., 1991), which in these
A17-Mrf4-nlacZ (and A17-Tk-nlacZ) transgenes is
uncoupled from later fetal expression. The fourth A17-
Mrf4-nlacZ line, 4M, expresses the transgene only in fetal
muscle from E13.5. In Fig. 5B, an E14 fetus shows strong X-
gal staining in proximal limb muscles, and in back muscles
and muscles of the neck and head.
Fig. 4. Transgene expression in the embryonic myotome. (A) X-gal staining of an A17-Tk-nlacZ transgenic embryo at E11.0 shows myotomal staining. (B) X-
gal staining of an embryo at E10.5 with a A17D-ba-Tk-nlacZ transgene, which includes the branchial arch (arrow) element at 1.8/0.7 kb 5V to the ATG of
the Myf5 gene, and in which the 15-bp core sequence in the A17 enhancer has been deleted. Myogenic expression is only seen in the branchial arches, as
expected, with some h-galactosidase activity in the neural tube and interlimb ectoderm. (C) X-gal staining of E9.75, 10.75, 11.5, and 12.5 embryos expressing
the A17-Mrf4-nlacZ transgene (line 44F) showing expression in a subdomain of the myotome, which is downregulated in rostral somites of more mature
embryos. (D) X-gal staining of aMyf5-nlacZ heterozygote embryo at E11.5, showing the full extent of myotomal expression, as well as expression at other sites
of myogenesis. (E) An enlargement of myotomes in the interlimb region of such an embryo at E10.75. (F) Interlimb somites after double labeling of an E10.75
A17-Mrf4-nlacZ transgenic embryo, stained with X-gal (blue) and subsequently hybridized in situ with an Engrailed1 riboprobe, visualized by BM-Purple
staining after reaction with an anti-Digoxigenin Alkaline Phosphatase conjugate antibody (purple). The h-galactosidase-positive cells lie within the region of
Engrailed1 expression, which characterizes the intercalated domain. The full extent of a somite in relation to the domain of Engrailed1 expression is outlined.
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56F) included the proximal element (1.8/0.7), which
drives expression in the branchial arches linked to the 291
bp Myf5 promoter (Summerbell et al., 2000), as a positive
control for embryonic expression of the transgene. None of
these lines showed X-gal staining of myogenic cells in the
embryo except in the branchial arches (Fig. 5D). The line 56F
expresses the transgene as well in the neural tube. Line 52M
displayed ectopic expression in neural crest derivatives, and
54M in presomitic mesoderm (results not shown), but not
restricted to the region where low level expression was
observed in embryos with nlacZ targeted to the Myf5 gene
(Cossu et al., 1996). However, all three lines expressed the
transgene in fetal muscles. X-gal staining on whole-mount
embryos (Figs. 5E and F), at E14.5 shows labeling of limb
muscles, body muscles, including the intercostals and rectus
abdominus (arrows), and neck and head muscles. The bran-
chial arch element probably also contributed to jaw muscle
expression (cf. Figs. 5A,B; Noden, 1983). Not all muscles
appear to be labeled to the same extent, notably those in the
more distal limb, and body wall muscles, compared to a
control y200-Myf5-nlacZ embryo at the same stage (Fig. 5C).By E17.5, when transverse cuts of the fetus were made to
facilitate X-gal staining, most major body muscle masses are
strongly labeled (results not shown). The effect of deleting
the core sequence of the enhancer (A17D) was also examined
at fetal stages with the Myf5 promoter. At E14.5, no skeletal
muscle expression in the trunk or limbs was observed in ten
transgenic embryos, six of which showed some h-galactosi-
dase labeling at ectopic sites. One embryo showed low-level
labeling in a few skeletal muscles (results not shown). These
results suggest that the core sequence plays a role in enhancer
activity in vivo, in fetal as well as embryonic skeletal muscle.
The A17-ba-Myf5-nlacZ lines (and one A17-Mrf4-nlacZ
line and the A17-Tk-nlacZ line) have a fetal expression profile
similar to that described for the second wave of Mrf4 trans-
cription (Bober et al., 1991;Hinterberger et al., 1991;Patapou-
tian et al., 1995), uncoupled from the earlier embryonic wave.Discussion
An enhancer trap approach in the C2 muscle cell line has
led to the isolation of a mouse genomic sequence in the 5V
Fig. 5. Transgene expression in foetal muscle. (A) X-gal staining of an embryo at E14.5 from the A17-Tk-nlacZ line. Intercostal muscles are indicated by an
arrowhead. (B) X-gal staining of an embryo at E14.5 from the A17-Mrf4-nlacZ transgenic line 4M. (C) X-gal staining at E14.5 of an embryo from the y200-
Myf5-nlacZ line showing the complete expression profile. (D) X-gal staining of an E10.5 embryo from the A17-ba-Myf5-nlacZ transgenic line 56F with labeled
myogenic cells in the branchial arches (arrow) only. In this line, the neural tube is also labeled. (E–F) X-gal staining of embryos at E14.5 from A17-ba-Myf5-
nlacZ 56F (E) and 52M (F) transgenic lines. Line 52M shows ectopic staining in the skin, particularly in the head. The rectus abdominus (arrow) and intercostal
muscles (arrowheads) are indicated.
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enhancer (A17) directs muscle specific expression of a
reporter gene either in the embryonic myotome or in later
fetal muscle. These two alternate modes are observed with a
nonmuscle Tk promoter while Mrf4 and Myf5 promoters
preferentially direct early or late expression, respectively, in
the transgenic lines examined.
The C2 cell line was derived from the limb muscle of
newborn mice (Yaffe and Saxel, 1977). Undifferentiated
myoblasts express Myf5 and MyoD and in the cells used in
these experiments, Mrf4 was also detectable (M.P., unpub-
lished). When the cells differentiate, transcripts of MyoD,
Myogenin andMrf4, accumulate (Montarras et al., 1991). The
enhancer trap assay was aimed at isolating Myf5 regulatory
sequences and therefore genomic fragments were screened in
myoblasts. Apart from repeat sequences resulting from
LINE1 retroviral insertions, only the A17 sequence, which
was isolated twice, had activity, within the 96-kb region
upstream of Myf5. A17 is active with Tk (170 bp), as well
as Myf5 (291 bp) and Mrf4 (385 bp) minimal promoters,and in the reverse orientation, consistent with enhancer
function. Several other sequences that are active with heter-
ologous promoters as well as that of Myf5 have been
identified in this region, notably at 58/48 kb (Hadchouel
et al., 2000, 2003) and at 6 kb (Summerbell et al., 2000;
Teboul et al., 2002). These sequences showed no activity in
C2 cells (results not shown). This may reflect their expression
in vivo, which is confined to embryonic stages. In keeping
with the expression of Myf5 in the C2 cell line, A17-Myf5-
nlacZ, which shows 10–30-fold enhancement in myoblasts,
is virtually inactive (2-fold) in differentiated myotubes.
However, its activity in vitro is not confined to undifferenti-
ated muscle cells; enhancement is also seen in other meso-
dermal cell lines. This is also the case for theMyoD enhancer
located at20 kb from the gene, which in vivo directs muscle
specific expression and in vitro is active in C2 cells and in the
10T1/2 fibroblast cell line (Goldhamer et al., 1992).
Further analysis of A17 activity in C2 myoblasts demon-
strated that this depends on a 15-bp core sequence with three
potentially interesting binding sites for homeodomain pro-
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homeodomain-binding site is identical to an optimized
sequence that binds a putative myogenic factor COMP1,
which cooperatively enhances Myogenin transactivation on
an adjacent E-box (Funk and Wright, 1992). This TGATT-
GAC sequence also corresponds to the Pbx Consensus
Element (PCE) defined for the Pbx family of proteins
(Knoepfler and Kamps, 1997), which are capable of coop-
erating with MRF complexes in DNA binding assays
(Knoepfler et al., 1999), but the experiments reported here
suggest that other proteins are binding to this site (bands B),
and may be exerting some repressor function in C2 myo-
blasts, since mutation of the site increases A17 activity.
Although AP-1 has been implicated in the regulation of
Myf5 (Aurade et al., 1997), there was no indication that the
AP-1 site in the A17 core is involved in binding activity. Site-
directed mutations indicated that the E-box is important for
activity. However, there was no indication that myogenic
factors regulate the enhancer through the E-box. Indeed,
myogenic conversion experiments in nonmuscle cells show
that the other myogenic factors cannot activateMyf5 (Aurade
et al., 1994) and in the Myf5 mutant where nlacZ is targeted
to both Myf5 alleles, the reporter gene is expressed correctly
(Tajbakhsh et al., 1996a), suggesting that autoregulation may
not be a major consideration. A17 is also active with the
promoter of Mrf4, a myogenic factor gene that can be
activated by other myogenic factors, but part of this may
take place via an E-box in the proximal promoter (Black et
al., 1995). USF binds to the E-box in the A17 core sequence
and overexpression of dominant-negative forms of USF1
and USF2 in C2 cells repress A17 activity. USF factors are
widely expressed in different tissue types and at different
developmental stages. Single null mutations are viable with
no obvious muscle phenotype, whereas the double USF1/
USF2 mutation is an early embryonic lethal (Sirito et al.,
1998) and therefore uninformative about USF function in
myogenesis. However, the observations on C2 muscle cells
and the fact that deletion of the 15-bp core sequence from the
A17 enhancer affects its activity in vivo, under conditions
where the branchial arch control element present in the
transgene is expressed, suggests a potential role for USF in
the regulation of the Mrf4–Myf5 locus in both embryonic
and fetal muscle. Myosin light chain-2v, expressed in slow
skeletal muscle, is regulated through a USF-binding site in
its promoter (Navankasattusas et al., 1994).
In vivo, the A17 enhancer directs transgene expression
specifically in skeletal muscle. Some ectopic expression is
seen with this short sequence, but it is variable between
lines, reflecting integration site effects. Two modes of
expression are observed, which appear to be mutually
exclusive. With the Tk and Mrf4 promoters, expression is
seen in embryonic skeletal muscle, in cells in the interca-
lated myotome. This region of the dorsal somite is marked
by Engrailed1 expression (Spo¨rle, 2001). The early epaxial
myotome assumes this more central position as the somite
elongates and it is in this intercalated region that differen-tiation is initiated, probably by Mrf4 (see Buckingham,
1994) during its first phase of expression (Patapoutian et
al., 1995; see also Smith et al., 1994). In one line, which
expressed the transgene at a high level, more extensive
myotomal expression was seen. This may reflect persistence
of h-galactosidase in cells that subsequently leave the
intercalated domain, or low level Mrf4 expression in myo-
tomal cells where the differentiation factor Myogenin pref-
erentially accumulates (Smith et al., 1994). The timing of
A17 activity corresponds to that described for the early
phase of Mrf4 expression (about E9.5–11.5). A transgene
with 8.5 kb of DNA flanking the rat Mrf4 gene driving a
lacZ reporter gene was expressed in the central myotome
although, unlike A17-Mrf4-nlacZ, this was only detected in
thoracic somites (Pin et al., 1997). Since 6.5-kb flanking
the mouse Mrf4 gene was not sufficient to drive myotomal
expression (Patapoutian et al., 1993), this is consistent with
the presence of the A17 enhancer, situated at 8 kb from
Mrf4. We have described a y23-Myf5-nlacZ transgene that is
expressed in part of the intercalated myotome (Hadchouel et
al., 2000), possibly due to A17 activity, although we did not
see embryonic muscle expression with A17-ba-Myf5-nlacZ
transgenes. A second element, which also targets the inter-
calated myotome, is present at 57.5/56.6 (Hadchouel et
al., 2003). This region of the somite is clearly a distinct
regulatory domain. In our transgenic lines, we saw no
indication of earlier expression in the hypaxial dermomyo-
tome, where Mrf4 is first expressed along with Myf5 in
muscle progenitor cells (Summerbell et al., 2002). Expres-
sion here is probably regulated by a distal element(s) at
more than 88 kb from Myf5 (Carvajal et al., 2001).
The second phase of Mrf4 expression in the fetus and
adult (Patapoutian et al., 1995) is partially regulated by
sequences within 8.5 kb of the rat Mrf4 gene (Pin et al.,
1997) to some extent reflecting regulatory sequences in the
6.5-kb flanking region (Patapoutian et al., 1993) within
which lie regulatory regions identified as active in C2 cells
(Kerkvliet and Hinterberger, 1997) and in the mouse fetus
(Pin and Konieczny, 2002). The proximal Mrf4 promoter
(385 bp), which directs no somitic expression, shows very
limited activity in a few fetal muscle fibers (Pin et al., 1997).
Transgenes with the A17 element show fetal muscle expres-
sion and an example of this was observed with both Tk and
Mrf4 promoters, indicating that this is driven by the en-
hancer sequence. Not all fetal muscles are equally labeled,
suggesting that other sequences are also necessary.
All three A17-ba-Myf5-nlacZ lines showed fetal and not
embryonic expression of the transgene. Muscles in the
head and neck and proximal limb muscles are most
strongly labeled, but h-galactosidase activity is also de-
tectable in trunk muscles such as the intercostals or rectus
abdominus. The branchial arch element probably contrib-
utes to head and neck expression, although some of this is
also seen with the Tk and Mrf4 promoter constructs. In the
context of the locus, we had described a region between
96/63 kb, which is required for the maintenance of
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body muscles such as the rectus abdominus (see also
Carvajal et al., 2001; Hadchouel et al., 2000). It is clear that
the A17 element with the branchial arch sequence and Myf5
proximal promoter alone does not require this maintenance
region for later expression, suggesting that either A17 does
not normally direct Myf5 expression or that there are nega-
tively acting elements elsewhere in the locus, which are
overcome by the upstream maintenance sequence. Embryon-
ic expression of Myf5, in the limbs and part of the somite,
depends on the sequence at 58/48 kb from the gene
(Hadchouel et al., 2003). However, at fetal stages, when this
region is deleted in the context of a BAC covering 195 kb of
the locus, Myf5-nlacZ expression becomes detectable in the
limbs from E12.5, initially in proximal muscles of the
forelimb. A17 is therefore a candidate regulatory sequence
for this later phase of Myf5 transcription.
In conjunction with the Myf5 or Mrf4 promoter, A17
therefore reflects aspects of the expression of the
corresponding genes. In the case of the Mrf4 and Tk
promoters, both embryonic and fetal modes of expression
were observed; however, in all the lines examined, these
were always mutually exclusive. The molecular explana-
tion for this striking observation is not clear. A DNAaseI
hypersensitive site was detected at about 8 kb from the
Mrf4 promoter in cultured C2 myoblasts (data not shown).
This corresponds to the location of A17, suggesting that
the enhancer is a target of chromatin regulation. The
importance of chromatin remodeling during myogenesis
is demonstrated by the role that Myf5 itself plays in
modifying the repressive chromatin structure over regula-
tory regions of genes such as Myogenin (Gerber et al.,
1997). In the case of the A17 transgenes, chromatin
modification may be influenced by the site of insertion,
such that the onset of embryonic or fetal expression is
affected. The second phase of expression does not appear
to overlap with the first and may involve a different cell
population, with distinct transcriptional requirements. The
relatively low number of expressing transgenic lines might
suggest that the enhancer is subject to silencing, which
could lead to the absence of embryonic or fetal expres-
sion. This may be mediated by chromosomal proteins such
as the HI linker proteins which inhibit MyoD induction in
Xenopus, or histone modification which has been shown
to regulate MyoD- and MEF2-mediated activation of
muscle genes (see Rupp et al., 2002). DNA methylation
mediated silencing may also be acting on the transgenes.
The distal enhancer of MyoD undergoes a regulated
demethylation in somitic cells before the gene is activated
in the mouse embryo, although methylation alone does not
appear to account for the silencing of an enhancer regu-
lated transgene in cells in which it is not normally
expressed (Brunk et al., 1996; see Rupp et al., 2002).
Epigenetic mechanisms of these kinds are probably acting
on the A17 transgene to varying degrees according to the
integration site.The tendency for A17-Mrf4-nlacZ transgenes to be
expressed in embryonic muscle, while the A17-ba-Myf5-
nlacZ lines obtained showed only later fetal expression,
suggests that the enhancer–promoter combination is not
neutral. Alone, the Mrf4 or Myf5 promoter sequences used
do not direct significant reporter gene expression, but the
implication is that they contain information which affects
A17 activity. There are many loci where enhancer–pro-
moter interactions have been studied in the context of the
spatiotemporal regulation of gene expression during de-
velopment. In the case of the HoxD cluster, a distant
enhancer directs the expression of a given promoter
according to its proximity; removing a gene (promoter)
confers its expression pattern on the succeeding gene in
the cluster (Kmita et al., 2002). The Igf2-H19 locus
provides another position-dependent model system, involv-
ing promoter competition for an endodermal enhancer. In
this case, an intergenic chromatin boundary regulates
promoter–enhancer interaction on an imprinted allele
(Webber et al., 1998). The h-globin cluster is a third
example where looping out of intervening chromatin
brings regulatory sequences in a distant locus control
region into the proximity of a h-globin gene (Tolhuis et
al., 2002). In the case of the Mrf4–Myf5 locus, it is not
clear how enhancers differentially affect the Mrf4 and
Myf5 promoters. A simple linear model does not appear
to apply since the 58/48 enhancer region interacts with
the Myf5 promoter to direct strong limb expression (Had-
chouel et al., 2003), although it is closer to the Mrf4 gene,
which is not expressed strongly in the limbs at the stage
when the enhancer is active. The results presented here
suggest that where the A17 enhancer is concerned, the
nature of the promoter, Mrf4 or Myf5, may influence the
expression pattern. Further deletion experiments in the
context of the locus will be necessary to clarify how the
A17 enhancer contributes to the distinct expression profiles
of Mrf4 and Myf5 during myogenesis.Acknowledgments
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